Top 10 Peptides for Weight Loss
The most effective peptides for weight loss, ranked by clinical evidence, efficacy, and real-world results.
⚡ Quick Compare Top 5The gold standard — FDA-approved with 15-17% body weight loss in clinical trials. Once-weekly dosing, massive evidence base, and proven cardiovascular benefits make it the undisputed #1.
An FDA-approved GLP-1 receptor agonist used for type 2 diabetes and chronic weight management, producing significant weight loss of 15-17% body weight in clinical trials.
The dual-agonist powerhouse hitting both GLP-1 and GIP receptors. Clinical trials show up to 22.5% weight loss — potentially surpassing semaglutide for pure efficacy.
A first-in-class dual GIP/GLP-1 receptor agonist that produces up to 22.5% body weight loss, approved for type 2 diabetes and obesity management.
The triple-agonist next-gen candidate (GLP-1/GIP/glucagon). Phase 2 showed 24% weight loss at 48 weeks — potentially the most powerful weight loss peptide ever studied.
An investigational triple-agonist peptide targeting GLP-1, GIP, and glucagon receptors, producing unprecedented weight loss of up to 24% in clinical trials.
A fragment of human growth hormone specifically targeting fat metabolism without the diabetogenic effects of full HGH. Popular in compounding pharmacies for its targeted fat-loss mechanism.
A modified fragment of human growth hormone (amino acids 176-191) that stimulates lipolysis and inhibits lipogenesis without the diabetogenic or growth-promoting effects of full-length HGH.
FDA-approved GHRH analog that specifically reduces visceral adipose tissue. Uniquely effective for stubborn belly fat, originally approved for HIV-associated lipodystrophy.
An FDA-approved synthetic analogue of growth hormone-releasing hormone (GHRH) with a trans-3-hexenoic acid modification, indicated for HIV-associated lipodystrophy and studied for cognitive benefits and visceral fat reduction.
A triple monoamine reuptake inhibitor originally developed for neurodegeneration that showed remarkable weight loss. Phase 2 data showed 10-13% weight loss — impressive for an oral agent.
A triple monoamine reuptake inhibitor (serotonin, norepinephrine, dopamine) originally developed for Parkinson's and Alzheimer's disease, repurposed as a potent weight-loss agent.
The classic GH-releasing stack. Boosts natural growth hormone pulsatility, improving fat metabolism and body composition while preserving lean mass during a cut.
The most popular growth hormone peptide combination, pairing a GHRH analog (CJC-1295) with a ghrelin mimetic (Ipamorelin) for synergistic GH release with minimal side effects.
Semaglutide's predecessor — FDA-approved for weight loss (Saxenda) with ~8% body weight loss. Daily dosing is less convenient but it has the longest safety track record of any GLP-1 for obesity.
An FDA-approved GLP-1 receptor agonist used for type 2 diabetes and obesity management, with cardiovascular and neuroprotective benefits.
A novel small molecule that inhibits NNMT enzyme, boosting NAD+ levels and shifting metabolism toward fat burning. Oral dosing and a unique mechanism make it an interesting addition to weight loss protocols.
A small molecule NNMT (nicotinamide N-methyltransferase) inhibitor that promotes fat loss by increasing NAD+ levels and cellular energy metabolism, available as an oral compound.
A mitochondrial-derived peptide that acts as an exercise mimetic, improving metabolic flexibility and glucose regulation. Particularly interesting for metabolic syndrome and insulin resistance.
A mitochondria-derived peptide that acts as an exercise mimetic, improving metabolic health, insulin sensitivity, and physical performance through AMPK activation.